Skip to main content
. 1997 Aug 29;186(5):695–704. doi: 10.1084/jem.186.5.695

Table 2.

Winn Type Tumor Neutralization by wt p53-specific CTL Clone 1H11

Tumor incidence
Tumor dose Control clone 9.5 wt p53-specific CTL clone 1H11
    5 × 104 4/4 1/4
    1 × 104 4/4 0/4
0.2 × 104 4/4 0/4

Immunocompetent B6 mice were simultaneously injected intraperitoneally with 5D (p53/N-ras) tumor cells at various doses and a control clone 9.5 (2 × 107) recognizing the HPV16 E7–derived epitope RAHYNIVTF or the wt p53-specific CTL clone 1H11 (2 × 107). On the day of treatment and 7 d later, a subcutaneous injection of 6 × 105 IU rIL-2 (Cetus Corp.) in 50% IFA was given.